Telix Pharmaceuticals will showcase four presentations at ASCO GU 2025, including preliminary data from the CUPID study demonstrating proof-of-concept for their alpha therapy candidate in prostate cancer.
The ProstACT GLOBAL trial is evaluating 177Lu-TLX591 plus standard of care (SOC) versus SOC alone in metastatic castration-resistant prostate cancer (mCRPC) patients.
PSMA-PET imaging with small molecule delivery of radionuclides is effective for defining intra-prostatic and metastatic prostate cancer, especially at low PSA levels.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.